| Description |
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies[1][2].
|
| Related Catalog |
|
| In Vitro |
Mazorelvimab (0.01-100 µg/mL) 以剂量依赖性方式对 CVS-11 感染的 BSR 细胞显示出细胞毒性，但对未感染的 BSR 细胞无影响[1]。
|
| In Vivo |
Mazorelvimab (0.03-1.0 mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高了被狂犬病毒 (RABV) 感染的仓鼠的存活率[1]。 Mazorelvimab (0.003-1mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高 RABV 感染的仓鼠的存活率。Mazorelvimab (0.003-0.03 mg/kg) 对未感染病毒的叙利亚仓鼠血清 RVNA 水平无显著干扰[2]。 Mazorelvimab (0.03-1 mg/kg；肌肉注射；单剂量) 对感染 RABV (BD06) 的比格犬具有保护作用[2]。 Animal Model: RABV infected Syrian hamster[1]. Dosage: 0.03, 0.1, 0.3 and 1.0 mg/kg. Administration: Right gastrocnemius muscle injection; single dose. Result: Improved the survival rate. Animal Model: 10 two-month-old female Syrian hamsters/six-month-old beagles infected with RABV (BD06)[2]. Dosage: 0.003, 0.01, 0.03, 0.1, 0.3 and 1 mg/kg. Administration: Right gastrocnemius muscle or masseter muscle injection; single dose. Result: Improved survival rate and had protective effect.
|
| References |
[1]. Chao TY, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133. [2]. Chao TY, et al. In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models. Trop Med Infect Dis. 2020 Feb 21;5(1):31.
|
